Salute e Benessere
Prostate Cancer Drugs Market to Reach USD 28.10 Billion by 2033 | According to DataM Intelligence
Prostate cancer treatment has evolved significantly over the last decade. Traditional androgen deprivation therapy (ADT) remains foundational, but next-generation agents-including and emerging immunotherapies-are redefining the therapeutic landscape.
By 2033, the market will increasingly shift toward biomarker-driven and combination therapy models, improving survival while reducing toxicity.
Hormonal therapy dominated the prostate cancer drugs market in 2024, contributing an estimated , equivalent to . Androgen receptor inhibitors (ARIs), CYP17 inhibitors, and GnRH analogues remain the cornerstone of prostate cancer treatment. The strong uptake of , , , and continues to drive segment revenue, especially for metastatic castration-resistant (mCRPC) and hormone-sensitive prostate cancer (mHSPC).
Hormonal therapy is expected to retain market leadership through 2033 due to the growing trend of earlier intervention and broader adoption across treatment lines.
Chemotherapy accounted for ( USD 2.37 billion ), with remaining the primary agents used for late-stage and aggressive disease. Combination regimens with AR therapies and PARP inhibitors are enhancing survival, supporting stable uptake.
Immunotherapy represented ( USD 1.45 billion ) in 2024. Agents such as , , and novel tumor-infiltrating lymphocyte (TIL) therapies are entering a new growth phase. Immunotherapies are particularly promising for MSI-H, high-tumor-mutational burden patients, and specific genetic subgroups.
Targeted therapy captured ( USD 1.85 billion ), driven by strong adoption of and . Lutetium-177–PSMA-617 (Pluvicto) saw double-digit growth driven by survival benefits in metastatic disease. With multiple PSMA radiotherapies and DNA-damage repair inhibitors advancing in clinical trials, this segment is expected to expand rapidly through 2033.
Oral therapies dominated with in 2024, representing , driven by oral hormonal therapies, PARP inhibitors, corticosteroids, and certain targeted therapies. The shift toward home-based cancer management since COVID-19 continues to accelerate oral drug adoption.
IV therapies accounted for ( USD 4.36 billion ), including chemotherapy (docetaxel, cabazitaxel), radioligand therapies (Pluvicto), immunotherapies (pembrolizumab), and bisphosphonates. The segment remains essential for advanced and metastatic cases.
Hospital pharmacies led the market with , equal to , due to the high use of IV chemotherapeutics, immunotherapies, radiotherapies, and complex oncology protocols.
Retail pharmacies contributed ( USD 3.30 billion ), driven by prescription renewals for oral hormonal agents and chronic management drugs.
Online pharmacies accounted for , about , with rapid growth in oncology telemedicine and patient-support digital channels.
(
The U.S. remained the largest global prostate cancer drug market in 2024, representing , approximately . High disease prevalence, strong reimbursement frameworks, rapid adoption of AR inhibitors, and FDA approvals are key growth factors.
The U.S. market is expected to exceed .
Japan contributed , equal to in 2024. The country has one of the fastest-growing elderly male populations in Asia , directly increasing prostate cancer treatment demand.
The Japanese market is expected to cross .
The prostate cancer therapeutics ecosystem is highly competitive, driven by blockbuster hormonal agents, expanding PARP inhibitor adoption, and strong late-stage pipeline development.
These companies collectively dominate more than , bolstered by strong oncology pipelines and multi-indication expansion strategies.
(
Between 2025 and 2033, several transformative shifts will shape the market:
By 2033, the prostate cancer drugs market will become one of the most evolved oncology markets, with targeted and personalized therapeutics driving survival gains and quality of life improvements.
1. Colorectal Cancer Drugs Market Size to Rise from US$ 12.60 B (2024) to US$ 19.96 B by 2033.
2. Blood Cancer Drugs Market Size to Surge Toward US$ 113.5 B by 2031 at 7.8% CAGR.
3. Ovarian Cancer Drugs Market Size Set to Rise to Over US$ 5.6 B by 2030 on Drug Innovation Surge.
4. Gastrointestinal Cancer Drugs Market Set to Reach Multi-Billion USD as Therapeutic Innovation Accelerates.
5. Skin Cancer Drugs Market Size to Soar at 10.2% CAGR Through 2031 - DataM Intelligence Forecast.
6. Breast Cancer Drugs Market Size to Surge from US$ 28.7 B in 2022 to US$ 57.1 B by 2031 at 9.2% CAGR.
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn, and Facebook.
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad , Telangana 500039
+1 877-441-4866
Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/prostate-cancer-drugs-market-to-reach-usd-28-10-billion-by-2033--according-to-datam-intelligence-302623116.html